Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which class of drugs inhibits the cyclooxygenase (COX) enzyme, thereby reducing prostaglandin synthesis and inflammation in conditions such as arthritis?

Nonsteroidal anti-inflammatory drugs. ***Nonsteroidal anti-inflammatory drugs*** - **NSAIDs** inhibit the **cyclooxygenase (COX) enzyme**, which is responsible for synthesizing **prostaglandins** from arachidonic acid. - By reducing prostaglandin synthesis, NSAIDs decrease **inflammation**, pain, and fever, making them effective in conditions like arthritis. *Corticosteroids* - **Corticosteroids** are potent anti-inflammatory drugs that act by inhibiting **phospholipase A2**, blocking the entire cascade of arachidonic acid metabolism, including both prostaglandins and leukotrienes. - They have broader immunosuppressive effects than NSAIDs but also carry a wider range of potential side effects with long-term use. *Opioids* - **Opioids** are powerful analgesics that work by binding to **opioid receptors** in the central nervous system, altering the perception of pain. - They do not directly inhibit **cyclooxygenase** or reduce **inflammation**, but rather provide symptomatic pain relief. *Antiepileptics* - **Antiepileptic drugs (AEDs)** primarily act on the central nervous system to reduce neuronal excitability and prevent seizures. - Some AEDs, like gabapentin or pregabalin, are also used for **neuropathic pain**, but they do not inhibit **COX enzymes** or reduce inflammation.

Q: A patient with rheumatoid arthritis is prescribed a disease-modifying antirheumatic drug (DMARD) that inhibits dihydroorotate dehydrogenase. Which drug is being used?

Leflunomide. ***Leflunomide*** - **Leflunomide** is an immunosuppressive DMARD that inhibits mitochondrial enzyme **dihydroorotate dehydrogenase**, an enzyme crucial for *de novo* pyrimidine synthesis. - This inhibition leads to a reduction in T-cell proliferation and cytokine production, making it effective in treating **rheumatoid arthritis**. *Methotrexate* - **Methotrexate** is a DMARD that primarily works by inhibiting **dihydrofolate reductase**, thus interfering with folate metabolism and purine synthesis. - Its mechanism is distinct from inhibiting dihydroorotate dehydrogenase and involves effects on various inflammatory pathways. *Sulfasalazine* - **Sulfasalazine** is an anti-inflammatory and immunomodulatory drug. Its mechanism of action in rheumatoid arthritis is not fully understood but involves metabolizing into **sulfapyridine** and **5-aminosalicylic acid**. - It does not directly inhibit dihydroorotate dehydrogenase; instead, it may modulate immune cell function and cytokine production. *Hydroxychloroquine* - **Hydroxychloroquine** is an antimalarial drug used in rheumatoid arthritis that inhibits **lysosomal activity** and antigen presentation, and modulates immune responses. - It does not target dihydroorotate dehydrogenase but rather interferes with intracellular signaling and cytokine release.

Q: Pegloticase is used for the treatment of which of the following?

Chronic tophaceous gout. ***Chronic tophaceous gout*** - Pegloticase is a **recombinant pegylated uricase** that metabolizes **uric acid** into allantoin, which is readily excreted by the kidneys. - It is specifically indicated for refractory chronic tophaceous gout when other therapies have failed. *Reactive Arthritis* - This condition is an **autoimmune response** to an infection elsewhere in the body, presenting with aseptic arthritis. - Treatment focuses on managing symptoms with **NSAIDs** and occasionally immune suppressants, not uric acid-lowering agents. *CPPD* - Also known as **pseudogout**, this condition is caused by the deposition of **calcium pyrophosphate dihydrate crystals** in joints. - Treatment involves **NSAIDs**, colchicine, or corticosteroids to manage acute flares, not uric acid-targeted therapies. *Refractory Rheumatoid arthritis* - Rheumatoid arthritis is a chronic inflammatory autoimmune disease primarily affecting the joints. - Treatment involves **DMARDs** (disease-modifying antirheumatic drugs) and biological agents, which target inflammation and immune response, not uric acid.

Q: What is the primary mechanism by which colchicine exerts its anti-inflammatory effects in acute gout?

Acts by inhibiting neutrophil migration. ***Acts by inhibiting neutrophil migration*** - Colchicine primarily functions by **disrupting microtubule formation** in neutrophils, which impairs their chemotaxis and migration to sites of inflammation. - This inhibition of neutrophil activity is crucial in dampening the **inflammatory response** triggered by uric acid crystals in acute gout. *Acts primarily as a uricosuric agent* - While other medications like **probenecid** are uricosuric and increase uric acid excretion, colchicine does not have this primary mechanism of action. - Its main anti-inflammatory effect is independent of uric acid metabolism or excretion. *Is the first-line treatment for chronic gout management* - Colchicine is effective for **acute gout attacks** and as a prophylactic against attacks during initiation of urate-lowering therapy. - However, **allopurinol** and **febuxostat** are the first-line treatments for chronic gout because they reduce uric acid production. *Has no effect on microtubule function* - This statement is incorrect; colchicine's entire mechanism of action is dependent on its ability to **bind to tubulin** and inhibit microtubule polymerization. - This disruption of microtubules is responsible for its anti-inflammatory effects and also its common side effects.

Q: Tocilizumab acts as an antagonist at which receptor?

IL-6. ***Correct: IL-6*** - **Tocilizumab** is a **monoclonal antibody** that specifically targets the **IL-6 receptor**, blocking the binding of **interleukin-6 (IL-6)** and inhibiting its pro-inflammatory effects. - This mechanism makes it effective in treating inflammatory conditions like **rheumatoid arthritis**, **giant cell arteritis**, and **cytokine release syndrome**. *Incorrect: IL-1* - **IL-1 antagonists**, such as **anakinra**, target the **IL-1 receptor** to block the inflammatory actions of **interleukin-1**. - These are typically used for conditions like **rheumatoid arthritis** and **cryopyrin-associated periodic syndromes (CAPS)**, distinct from tocilizumab's mechanism. *Incorrect: IL-2* - **IL-2 receptor antagonists**, such as **basiliximab** and **daclizumab**, are primarily used to prevent **organ transplant rejection** by inhibiting **T-cell activation**. - Their mechanism is different from **tocilizumab**, which targets a different cytokine pathway. *Incorrect: TNF-alpha* - **TNF-alpha inhibitors**, like **adalimumab** or **infliximab**, block the activity of **tumor necrosis factor-alpha**, a key cytokine in inflammation. - These agents are widely used for diseases such as **rheumatoid arthritis**, **psoriasis**, and **Crohn's disease**, but they operate on a different pathway than tocilizumab.

Q: Which of the following is the most potent opioid?

Sufentanil. ***Sufentanil*** - **Sufentanil** is a very potent synthetic opioid, estimated to be 5 to 10 times more potent than fentanyl and 500 to 1000 times more potent than morphine. - Its high potency is due to its strong binding affinity for **mu-opioid receptors** and rapid onset of action. *Butorphanol* - **Butorphanol** is a mixed opioid agonist-antagonist, acting as a partial agonist or antagonist at mu-opioid receptors and an agonist at kappa-opioid receptors. - While it provides analgesia, its efficacy is limited compared to full agonists due to its mixed receptor profile. *Pentazocine* - **Pentazocine** is another mixed opioid agonist-antagonist, primarily a kappa-opioid receptor agonist and a weak mu-opioid receptor antagonist or partial agonist. - It has a lower analgesic ceiling and can precipitate withdrawal in patients dependent on full mu-opioid agonists. *Hydrocodone* - **Hydrocodone** is an opioid agonist primarily used for moderate to severe pain, typically found in combination with acetaminophen. - Its potency is comparable to morphine, making it significantly less potent than ultra-potent synthetic opioids like sufentanil.

Q: Which of the following is a naturally occurring opioid?

Morphine. ***Morphine*** - **Morphine** is a naturally occurring **opioid alkaloid** found in the **opium poppy** (Papaver somniferum). - It is one of the most potent **analgesics** and is widely used for severe pain. *Ethylmorphine* - **Ethylmorphine** is a **semisynthetic opioid** derived from morphine by **ethylation**. - It is currently used primarily as an **antitussive** (cough suppressant). *Pholcodeine* - **Pholcodeine** is a **semisynthetic opioid** that acts as a **cough suppressant**. - It works by depressing the **cough reflex** in the brainstem. *Diacetylmorphine* - **Diacetylmorphine**, commonly known as **heroin**, is a **semisynthetic opioid** synthesized from morphine. - It is highly potent and rapidly crosses the **blood-brain barrier**, producing intense effects.

Q: Which T cell surface molecule's co-stimulatory function is blocked by Abatacept?

CD28. ***CD28*** - **Abatacept** is a fusion protein that binds to **CD80** and **CD86** on antigen-presenting cells (APCs). - This binding prevents the interaction of **CD80/CD86** with **CD28** on T cells, thereby blocking the critical co-stimulatory signal required for full T-cell activation [1]. *CD11* - **CD11** is part of the **integrin** family (e.g., CD11b/CD18, known as Mac-1 or CR3) and is involved in cell adhesion and migration, primarily on myeloid cells. - It does not directly participate in the **T-cell co-stimulation pathway** targeted by abatacept. *CD20* - **CD20** is a B-cell specific surface molecule that is the target of **rituximab**, a monoclonal antibody used in various lymphomas and autoimmune diseases. - It is not expressed on T cells and therefore not involved in **T-cell co-stimulation** blocked by abatacept. *CD22* - **CD22** is a **B-cell co-receptor** molecule involved in B-cell activation and signaling, acting as a negative regulator. - It does not play a direct role in the **co-stimulatory signals** between APCs and T cells that are modulated by abatacept.

Q: Rasburicase is a recombinant form of which enzyme?

Urate Oxidase. ***Urate Oxidase*** - **Rasburicase** is a recombinant **urate oxidase** enzyme that catalyzes the oxidation of uric acid into allantoin. - This conversion makes uric acid more soluble and easier to excrete, thereby lowering serum uric acid levels, which is crucial in managing or preventing **tumor lysis syndrome** [2]. *Xanthine oxidase* - **Xanthine oxidase** is involved in the catabolism of purines, converting xanthine to uric acid [1]. - **Allopurinol**, a common drug for hyperuricemia, inhibits xanthine oxidase, but rasburicase does not act as an analogue or inhibitor of this enzyme [3], [4]. *IMP dehydrogenase* - **IMP dehydrogenase** is an enzyme involved in the de novo synthesis of guanine nucleotides from inosine monophosphate (IMP). - It is not directly involved in the catabolism of uric acid, and rasburicase has no known functional analogy to it. *Adenosine Deaminase* - **Adenosine deaminase** is an enzyme that catalyzes the deamination of adenosine to inosine. - Its deficiency is associated with a severe combined immunodeficiency (SCID), and it plays no direct role in uric acid metabolism related to rasburicase's action.

Question 1

Which class of drugs inhibits the cyclooxygenase (COX) enzyme, thereby reducing prostaglandin synthesis and inflammation in conditions such as arthritis?

Accepted Answer

Nonsteroidal anti-inflammatory drugs

Answer

Corticosteroids

Answer

Opioids

Answer

Antiepileptics

Question 2

A patient with rheumatoid arthritis is prescribed a disease-modifying antirheumatic drug (DMARD) that inhibits dihydroorotate dehydrogenase. Which drug is being used?

Accepted Answer

Leflunomide

Answer

Methotrexate

Answer

Sulfasalazine

Answer

Hydroxychloroquine

Question 3

A patient with severe cancer pain is on high-dose morphine but is experiencing uncontrolled pain and side effects. What is the best next step?

Accepted Answer

Switch to methadone for its NMDA receptor antagonism

Answer

Add a non-steroidal anti-inflammatory drug (NSAID)

Answer

Increase the morphine dose and monitor side effects

Answer

Discontinue morphine and switch to fentanyl

Question 4

Pegloticase is used for the treatment of which of the following?

Accepted Answer

Chronic tophaceous gout

Answer

Reactive Arthritis

Answer

CPPD

Answer

Refractory Rheumatoid arthritis

Question 5

What is the primary mechanism by which colchicine exerts its anti-inflammatory effects in acute gout?

Accepted Answer

Acts by inhibiting neutrophil migration

Answer

Acts primarily as a uricosuric agent

Answer

Is the first-line treatment for chronic gout management

Answer

Has no effect on microtubule function

Question 6

Tocilizumab acts as an antagonist at which receptor?

Accepted Answer

IL-6

Answer

IL-1

Answer

IL-2

Answer

TNF-alpha

Question 7

Which of the following is the most potent opioid?

Accepted Answer

Sufentanil

Answer

Butorphanol

Answer

Pentazocine

Answer

Hydrocodone

Question 8

Which of the following is a naturally occurring opioid?

Accepted Answer

Morphine

Answer

Pholcodeine

Answer

Ethylmorphine

Answer

Diacetylmorphine

Question 9

Which T cell surface molecule's co-stimulatory function is blocked by Abatacept?

Accepted Answer

CD28

Answer

CD11

Answer

CD20

Answer

CD22

Question 10

Rasburicase is a recombinant form of which enzyme?

Accepted Answer

Urate Oxidase

Answer

Xanthine oxidase

Answer

IMP dehydrogenase

Answer

Adenosine Deaminase

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?